Stock SLNCF SILENCE THERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Silence Therapeutics plc OTC Markets

Equities

SLNCF

GB00B9GTXM62

Market Closed - OTC Markets
Other stock markets
 12:02:30 2024-06-26 pm EDT 		5-day change 1st Jan Change
6.5 USD 0.00% Intraday chart for Silence Therapeutics plc 0.00% +333.33%
Jun. 28 European Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading MT
Jun. 28 Chardan Raises Price Target on Silence Therapeutics to $55 From $42, Maintains Buy Rating MT

Analyst Reco.

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Chardan Raises Price Target on Silence Therapeutics to $55 From $42, Maintains Buy Rating
MT
Morgan Stanley Raises Price Target on Silence Therapeutics to $49 From $45, Keeps Overweight Rating
MT
Chardan Boosts Price Target on Silence Therapeutics to $42 From $26 on Positive Data From Zerlasiran Study, Keeps Buy Rating
MT
Morgan Stanley Boosts Price Target on Silence Therapeutics to $45 From $29, Says Q4 Showed 'Meaningful Progress,' Keeps Overweight Rating
MT
BMO Capital Starts Silence Therapeutics With Outperform Rating, $67 Price Target
MT
HC Wainwright Adjusts Silence Therapeutics Price Target to $75 From $80, Maintains Buy Rating
MT
Chardan Adjusts Price Target on Silence Therapeutics to $26 From $29, Maintains Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SLN Stock
  4. SLNCF Stock
  5. News Silence Therapeutics plc
  6. Analyst Reco.